RxDoctor Payments Data

Kinston Cummings

Dermatology · Modesto, CANPI 1295462778

Payments from drug & device makers

$3,757in general payments, 2019–2025

Across 131 payments — averaging $28.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$703
  • AbbVie$540
  • Regeneron Healthcare Solutions, Inc.$446
  • Sanofi$419
  • Incyte Corporation$416
  • Novartis$388
  • plus $845 from 9 others

What the payments were for

  • Food & beverage$3,56395%
  • Education$1945%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,757 in reported general payments places this provider in the 60th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$435,421
Medicare patients
606
Services billed
9,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa22$435,812
Dupixent PenDupilumab71$248,694
Cosentyx Sensoready (2 Pens)Secukinumab30$242,220
Cosentyx Unoready PenSecukinumab17$154,728
Humira PenAdalimumab11$132,839
OpzeluraRuxolitinib Phosphate13$24,293
ZoryveRoflumilast15$15,126
Clobetasol Propionate249$11,180
Desonide90$7,325
Tacrolimus40$6,038
Ketoconazole168$5,527
Fluocinonide47$2,494
Tretinoin21$1,901
Metronidazole23$1,478
Doxycycline Hyclate49$1,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$416$24,29313 claims
Arcutis Biotherapeutics, Inc.Zoryve$119$15,12615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,875 dermatology providers in California.

Other dermatology in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →